Cancer drug development tends to focus on inhibiting protein activity rather than modulating protein levels. While this approach has seen some success, it comes with challenges, such as long-term resistance and toxicity. Targeted protein degradation offers a potential solution to this problem.
Protein degraders are small molecules that induce degradation and remove deleterious proteins from afflicted cells by modulating E3 ligase ubiquitination activity. In this webinar brought to you by The Scientist and sponsored by PerkinElmer|Cisbio, researchers will discuss how small-molecule degraders work, key points of interest in their design, and their applications in both the laboratory and the clinic.
Topics to be covered
- Using proteolysis targeting chimera (PROTAC) technology to overcome on-target toxicity of anticancer agents
- Structure-based design approaches for developing PROTACs against cancer
Meet the Speakers:
Daohong Zhou, MD
Professor of Pharmacodynamics...
Aileen Frost, PhD
Alessio Ciulli Research Group
Medicinal Chemist and Organic Chemistry Scientist
Biological Chemistry and Drug Discovery, School of Life Sciences
University of Dundee